Prevalence of Pathogenic Antibodies in Psychosis (PPiP2)
The aim of the PPiP2 study is to assess the number of patients suffering from psychosis that also have anti-neuronal membrane antibodies which might be causing their illness.
Study of Immunology in Antibody Positive Psychosis (SINAPPS)1
SINAPPS1 was a phase one study and it investigated the feasibility of delivering immunotherapy to patients with psychosis in a general hospital setting. The study was conducted from October 2015 to July 2017.
Click here for more information.
Study of Immunology in Antibody Positive Psychosis (SINAPPS2)
The SINAPP2 trial is a randomised, placebo-controlled clinical trial, investigating the efficacy and safety of immunotherapy as a treatment for symptoms of psychosis in patients with anti-neuronal membrane antibodies.
Click here for more information
Prevalence of Pathogenic Antibodies in Psychosis (PPiP)1
The PPiP1 study investigated prevalence of patients with anti-neuronal membrane antibodies included who were experiencing their first episode of psychosis in comparison with a group of healthy participants. The study was conducted from January 2013 – December 2014.